Last reviewed: June 20, 2026
Last updated: June 20, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both Zepbound (tirzepatide) and Wegovy (semaglutide) reduce hunger and slow digestion, yet they activate different pathways in your body. Tirzepatide targets two hormone receptors—GLP-1 and GIP—while semaglutide targets GLP-1 alone, which explains why clinical data shows tirzepatide produces greater average weight loss in head-to-head studies.
How Zepbound and Wegovy Work in Your Body
Zepbound (tirzepatide) is a dual-action medication that activates both GLP-1 and GIP receptors in the brain and gut. This double mechanism increases feelings of fullness, reduces appetite signals, and slows how quickly food moves through your digestive system. The combination of two hormone pathways allows tirzepatide to produce stronger satiety effects than single-pathway medications.
Wegovy (semaglutide) activates only the GLP-1 receptor, which also suppresses appetite and slows gastric emptying. While highly effective, semaglutide's single-target approach produces a narrower range of metabolic changes than tirzepatide. Both medications are injected once weekly and carry similar side effect profiles, though the intensity of side effects may differ based on individual tolerance.
Weight Loss Outcomes: Clinical Trial Data Comparison
In the SURMOUNT-1 trial, tirzepatide recipients achieved average weight losses of 22.5% of baseline body weight over 72 weeks at the highest dose. Semaglutide demonstrated average weight loss of 17.4% in the STEP-4 trial, also measured across 68 weeks. These differences reflect tirzepatide's dual-receptor activation, which engages both appetite suppression pathways simultaneously rather than relying on a single mechanism.
Individual responses to each medication vary widely based on genetics, lifestyle, and metabolic factors. Some patients achieve their goals faster on tirzepatide, while others find semaglutide sufficient and prefer to start with a single-pathway agent. PlexusDx uses the Precision Peptide Genetic Test to identify your genetic predispositions in pathways like GLP1R (rs6923761) and GIPR (rs1800437), helping match you to the medication most likely to work for your biology.
Cost, Access, and Treatment Flexibility
Zepbound (branded tirzepatide) carries substantial out-of-pocket costs for uninsured patients, often exceeding $900 monthly. PlexusDx offers compounded tirzepatide injection starting at $289/mo (or $249/mo on the 6-month plan) from licensed 503A pharmacies—a fraction of branded pricing—with no insurance requirement, no membership fee, and HSA/FSA eligibility. Your dose may increase during treatment, but your monthly price stays flat.
Wegovy (branded semaglutide) similarly carries high retail costs, though PlexusDx provides compounded semaglutide injection from licensed 503A pharmacies starting at $189/mo (or $149/mo on the 6-month plan). Both compounded options deliver bioidentical medications manufactured under pharmaceutical-grade standards. PlexusDx serves all 50 states, eliminating geographic barriers to access and allowing you to choose based on clinical fit rather than insurance coverage alone.
Side Effects, Tolerability, and Safety Considerations
Both tirzepatide and semaglutide commonly cause nausea, vomiting, constipation, and reduced appetite during the first few weeks of treatment. These effects typically diminish as your body adjusts, though they persist in some patients. Tirzepatide recipients report slightly higher rates of gastrointestinal side effects in trials, though the difference is modest and often manageable with gradual dose escalation and dietary adjustments.
Serious adverse events are rare with both medications when used as directed. Contraindications include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2. Pregnancy is not recommended during treatment. Regular monitoring by a healthcare provider ensures early detection of any complications and allows dose adjustments if side effects become intolerable.
Choosing Between Tirzepatide and Semaglutide for Your Goals
If your goal is maximum weight loss and you tolerate dual-receptor activation well, tirzepatide (Zepbound) typically outperforms semaglutide across clinical trials. If you prefer starting with a single-pathway medication, want to assess tolerability before advancing, or have specific medical factors favoring GLP-1 monotherapy, semaglutide (Wegovy) remains highly effective. Your genetics, current metabolic health, and past medication responses all inform this choice.
The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Does Zepbound work faster than Wegovy for weight loss?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Can I switch from Wegovy to Zepbound if I'm not seeing results?
Yes, switching from semaglutide to tirzepatide is medically appropriate if weight loss plateaus or remains insufficient after 3-6 months of treatment at therapeutic doses. The transition typically requires a washout period and restart at low tirzepatide doses. Your PlexusDx provider can manage this transition safely and monitor for any interactions or side effect changes.
Which medication costs less per month with PlexusDx?
PlexusDx compounded semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan), while compounded tirzepatide starts at $289 monthly across all commitment tiers. Both are significantly less expensive than branded Wegovy or Zepbound. Prices remain flat regardless of dose increases, ensuring predictable costs throughout your treatment.
Are compounded versions as effective as branded Zepbound and Wegovy?
PlexusDx compounded medications contain bioidentical tirzepatide and semaglutide manufactured in licensed 503A pharmacies under pharmaceutical-grade standards. Compounded versions deliver the same active ingredients as brand-name products, though they are not FDA-approved. Clinical effectiveness depends on consistent dosing and adherence, both supported by PlexusDx's flat-price model.
How does the Precision Peptide Genetic Test help me choose between these two?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Eat Potatoes on Wegovy? A Comprehensive Guide to Your Diet
Can You Switch from Mounjaro to Zepbound? Understanding the Transition